scholarly journals Optical Coherence Tomography Biomarkers Predicting Visual Acuity Change after Intravitreal Bevacizumab Injections for Macular Edema Secondary to Branch Retinal Vein Occlusion

2021 ◽  
Author(s):  
Ori Segal ◽  
Roy Yavnieli ◽  
Michael Mimouni ◽  
Gilad Rabina ◽  
Noa Geffen ◽  
...  
2015 ◽  
Vol 68 (9-10) ◽  
pp. 295-300
Author(s):  
Jelena Karadzic ◽  
Igor Kovacevic ◽  
Jelena Ljikar ◽  
Zorka Grgic ◽  
Gordana Devecerski

Introduction. Macular edema is the main cause of visual loss in patients with branch retinal vein occlusion. Macular edema is initially reversible, but over time, permanent loss of vision occurs from structural damage to the macula. For this reason, there is a need for more rapid and effective treatments than laser photocoagulation which has been established as a gold standard. There are several pharmacologic agents which have changed the management of macular edema. Material and Methods. Twenty eyes of 20 consecutive patients of the Department of Eye Diseases, Clinical Center of Vojvodina, in Novi Sad, were enrolled in this prospective, randomized and consecutive study conducted from January 2012 to January 2013. The patients were randomly assigned into two treatment groups, and they were given an intravitreal injection of bevacizumab 1.25 mg/0.05 mL (Avastin?), or triamcinolone acetonid injection 4 mg/0.1mL (Kenalog?). Reinjections were performed according to the following retreatment criteria a loss of visual acuity or increase in central retinal thickness. Results. Both intravitreal bevacizumab and triamcinolonacetonid were very effective in reducing macular edema and improving visual acuity in the eyes with macular edema secondary to retinal vein occlusion. The effect of the treatment was more pronounced if it started early after the onset of macular edema. The reported temporary effects of intravitreal triamcinolon- acetonide and bevacizumab could be explained by their clearance from the eye. Conclusion. The short-term results of our clinical trial showed that pharmacological intravitreal agents, such as bevacizumab and triamcinolon-acetonid, lead to rapid resolution of macular edema and significant improvement of visual acuity.


2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Tetsuju Sekiryu ◽  
Tomohiro Iida ◽  
Eiichi Sakai ◽  
Ichiro Maruko ◽  
Akira Ojima ◽  
...  

Purpose. To describe the findings of fundus autofluorescence (FAF) and optical coherence tomography (OCT) in patients with branch retinal vein occlusion (BRVO).Methods. In this institutional, retrospective, observational case series, FAF was evaluated in 65 eyes with BRVO in 64 consecutive patients and compared with visual acuity, OCT findings, and other clinical observations.Results. Five types of autofluorescence appeared during the course of BRVO: (1) petaloid-shaped hyperautofluorescence in the area of macular edema and (2) hyperautofluorescence coincident with yellow subretinal deposits. (3) Diffuse hyperautofluorescence appeared within the area of serous retinal detachment (SRD) and OCT showed precipitates on the undersurface of the retina in 5/5 of these eyes (100%). (4) The area of vein occlusion showed diffuse hyperautofluorescence after resolution of the retinal bleeding. (5) Hard exudates exhibited hyper- or hypoautofluorescence. OCT indicated that most of the hard exudates with hyperautofluorescence were located on the retinal pigment epithelium.Conclusions. Hyperautofluorescence associated with subretinal fluid or hard exudate appeared in the subretinal space. This type of hyperautofluorescence may be attributed to blood cell or macrophages. FAF and OCT are noninvasive modalities that provide additional information regarding macular edema due to BRVO.


Sign in / Sign up

Export Citation Format

Share Document